Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, Glenmark Pharmaceuticals has informed that SES ESG Research vide its email dated January 04, 2026, has assigned an ESG rating of ‘71.1’ for F.Y. 2025. The company has clarified that the Company has not engaged SES ESG for ESG Rating. SES ESG has independently assigned the rating based on publicly available information for F.Y. 2025.
The above information is a part of company’s filings submitted to BSE.
